Patents by Inventor Albert Cupo
Albert Cupo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10106583Abstract: Expression vectors and mammalian cell lines containing them are described that enable the recombinant production of HIV-1 envelope proteins, including SOSIP modified gp140 trimers capable of inducing broadly neutralizing antibodies.Type: GrantFiled: March 9, 2015Date of Patent: October 23, 2018Assignee: CORNELL UNIVERSITYInventors: Andre Marozsan, Albert Cupo, John Moore
-
Patent number: 9738688Abstract: The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.Type: GrantFiled: November 5, 2013Date of Patent: August 22, 2017Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, CORNELL UNIVERSITYInventors: Michael Caulfield, Albert Cupo, Hansi Dean, Simon Hoffenberg, C. Richter King, P. J. Klasse, Andre Marozsan, John P. Moore, Rogier W. Sanders, Andrew Ward, Ian Wilson, Jean-Philippe Julien
-
Publication number: 20170015711Abstract: Expression vectors and mammalian cell lines containing them are described that enable the recombinant production of HIV-1 envelope proteins, including SOSIP modified gp140 trimers capable of inducing broadly neutralizing antibodies.Type: ApplicationFiled: March 9, 2015Publication date: January 19, 2017Inventors: Andre Marozsan, Albert Cupo, John Moore
-
Publication number: 20150175681Abstract: Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.Type: ApplicationFiled: March 9, 2015Publication date: June 25, 2015Inventors: Dangshe Ma, Kirsten Nagashima, Brian Kennedy, Gerald P. Donovan, Yun Kang, William C. Olson, Shankar Kumar, Naoya Tsurushita, Andre J. Marozsan, Albert Cupo
-
Patent number: 8986697Abstract: Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.Type: GrantFiled: April 15, 2011Date of Patent: March 24, 2015Assignee: Progenics Pharmaceuticals, Inc.Inventors: Dangshe Ma, Kirsten Nagashima, Brian Kennedy, Gerald P. Donovan, Yun Kang, William C. Olson, Shankar Kumar, Naoya Tsurushita, Andre J. Marozsan, Albert Cupo
-
Publication number: 20140212458Abstract: The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron micrsocopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.Type: ApplicationFiled: November 5, 2013Publication date: July 31, 2014Applicants: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, CORNELL CENTER FOR TECHNOLOGY ENTERPRISE AND COMMERCIALIZATIONInventors: Michael Caulfield, Albert Cupo, Hansi Dean, Simon Hoffenberg, C. Richter King, P. J. Klasse, Andre Marozsan, John P. Moore, Rogier W. Sanders, Andrew Ward, Ian Wilson, Jean-Philippe Julien
-
Publication number: 20130202618Abstract: Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.Type: ApplicationFiled: April 15, 2011Publication date: August 8, 2013Applicant: Progenics Pharmaceuticals, Inc.Inventors: Dangshe Ma, Kirsten Nagashima, Brian Kennedy, Gerald P. Donovan, Yun Kang, William C. Olson, Shankar Kumar, Naoya Tsurushita, Andre J. Marozsan, Albert Cupo
-
Patent number: 5633167Abstract: Methods for blood sample preparation using reagent compositions which include a zwitterionic surfactant for sphering of cells to eliminate orientational noise. When the reagent composition including a dye for staining a subset of cells is reacted with a blood sample, and the reaction mixture is passed through the sensing region of a flow cytometer, the light scattered and absorbed by each cell is measured, the stained cells can be distinguished from the unstained cells, and when the cells are reticulocytes and mature erythrocytes, respectively, the volume and hemoglobin concentration of each reticulocyte or erythrocyte, and the hemoglobin content, mean cell volume, mean corpuscular hemoglobin concentration, and mean cell hemoglobin of the reticulocytes or erythrocytes are calculated from the measured cell-by-cell volume and hemoglobin concentration.Type: GrantFiled: December 22, 1994Date of Patent: May 27, 1997Assignees: Bayer Corporation, Mt. Sinai School of Medicine of the City Univ. of New YorkInventors: Sophie S. Fan, Daniel Ben-David, Albert Cupo, Gena Fischer, Grace E. Martin, Leonard Ornstein, Gregory M. Colella
-
Patent number: 5438003Abstract: A reagent composition which includes organic cationic dyes for staining the reticulocytes in a blood sample and buffer solutions for maintaining a pH of about 6 to about 9 is provided. The dyes may be the blue absorption dyes Oxazine 750 or New Methylene Blue. A zwitterionic surfactant is included in the reagent composition for isovolumetric sphering of the reticulocytes and erythrocytes. The reagent composition and whole blood sample mixture are passed through the sensing region of a flow cytometer. The light scattered and absorbed by each cell is measured; the erythrocytes can be distinguished from reticulocytes and the volume, hemoglobin concentration and the hemoglobin content of each reticulocyte or erythrocyte, and the mean cell volume, mean corpuscular hemoglobin concentration, and mean cell hemoglobin of the reticulocytes or erythrocytes are calculated from the measured cell-by-cell volume and hemoglobin concentration.Type: GrantFiled: October 15, 1992Date of Patent: August 1, 1995Assignees: Miles Inc., Mount Sinai School of Medicine of the City University of New YorkInventors: Gregory M. Colella, Daniel Ben-David, Albert Cupo, Sophie S. Fan, Gena Fischer, Grace E. Martin, Leonard Ornstein
-
Patent number: 5411891Abstract: A reagent composition which include an organic cationic dye for staining the reticulocytes in the blood sample and a buffer solution for maintaining a pH of about 6 to about 9 is provided. The dyes may be the red excitable fluorescent dye Oxazine 750, or the blue excitable fluorescent dyes Acridine Orange or derivatives of Acridine Orange. A zwitterionic surfactant is included in the reagent composition for isovolumetric sphering of the reticulocytes and erythrocytes.Type: GrantFiled: October 15, 1992Date of Patent: May 2, 1995Assignees: Miles Inc., Mount Sinai School of Medicine of the City University of New YorkInventors: Sophie S. Fan, Daniel Ben-David, Gregory M. Colella, Albert Cupo, Gena Fischer, Leonard Ornstein
-
Patent number: 5360739Abstract: Methods for characterizing and distinguishing reticulocytes and mature red blood cells use reagent compositions which include an organic cationic dye for staining the reticulocytes in the blood sample and a buffer solution for maintaining a pH of about 6 to about 9. The dyes may be the red excitable fluorescent dye Oxazine 750, or the blue excitable fluorescent dyes Acridine Orange or derivatives of Acridine Orange.Type: GrantFiled: December 5, 1991Date of Patent: November 1, 1994Assignees: Miles Inc., Mount Sinai School of Medicine of the City University of New YorkInventors: Sophie S. Fan, Daniel Ben-David, Gregory M. Colella, Albert Cupo, Gena Fischer, Leonard Ornstein
-
Patent number: 5350695Abstract: Methods for characterizing and distinguishing reticulocytes and mature red blood cells use reagent compositions which include organic cationic dyes for staining the reticulocytes in the blood sample and buffer solutions for maintaining a pH of about 6 to about 9. The dyes may be the blue absorption dyes Oxazine 750 or New Methylene Blue.Type: GrantFiled: December 5, 1991Date of Patent: September 27, 1994Assignees: Miles Inc., Mount Sinai School of Medicine of the City University of New YorkInventors: Gregory M. Colella, Daniel Ben-David, Albert Cupo, Sophie S. Fan, Gena Fischer, Grace E. Martin, Leonard Ornstein
-
Patent number: 5284771Abstract: Methods for blood sample preparation using reagent compositions which include a zwitterionic surfactant for sphering of cells to eliminate orientational noise. When the reagent composition including a for staining a subset of cells is reacted with an anticoagulated blood sample, and the reaction mixture is passed through the sensing region of a flow cytometer, the light scattered and absorbed by each cell is measured, the stained cells can be distinguished from the unstained cells, and when the cells are reticulocytes and mature erythrocytes, respectively, the volume and hemoglobin concentration of each reticulocyte or erythrocyte, and the hemoglobin content, mean cell volume, mean corpuscular hemoglobin concentration, and mean cell hemoglobin of the reticulocytes or erythrocytes are calculated from the measured cell-by-cell volume and hemoglobin concentration.Type: GrantFiled: December 5, 1991Date of Patent: February 8, 1994Assignees: Miles Inc., The Mount Sinai School of MedicineInventors: Sophie S. Fan, Daniel Ben-David, Albert Cupo, Gena Fischer, Grace E. Martin, Leonard Ornstein, Gregory M. Colella